Table 1—

Demographic details of a cohort of 788 HIV-infected patients with and without metabolic syndrome by IDF and ATPIII criteria

CharacteristicIDF
ATPIII
Metabolic syndromeNo metabolic syndromeP valueMetabolic syndromeNo metabolic syndromeP value
n114674139649
Male83 (73)580 (86)0.0003118 (85)545 (79)
Age (years)45 ± 1041 ± 9<0.000146 (9)41 (9)<0.0001
BMI (kg/m2)27 ± 423 ± 3<0.000126 (5)23 (3)<0.0001
Systolic BP (mmHg)130 ± 15122 ± 15<0.0001134 ± 16121 ± 14<0.0001
Diastolic BP (mmHg)81 ± 1076 ± 100.2381 ± 1075 ± 10<0.0001
HIV duration (years)8.1 ± 4.07.8 ± 5.00.059.0 (4)7.5 (5)0.01
Lipodystrophy cases83 (73)368 (55)0.31110 (79)341 (53)<0.001
CDC categories0.05
    Category A59 (52)338 (50)60 (43)337 (52)
    Category B31 (27)153 (23)31 (22)153 (24)
    Category C24 (21)184 (27)48 (35)159 (24)
Current drug therapies
    NRTI102 (89)572 (86)0.3124 (89)550 (86)0.29
        Lamivudine82 (72)417 (63)92 (66)409 (64)
        Zidovudine37 (32)217 (33)45 (32)209 (33)
        Stavudine55 (48)266 (40)63 (45)258 (40)
        Abacavir85 (21)47 (23)29 (21)103 (16)
        Didanosine13 (11)129 (19)23 (17)119 (19)
    NNRTI41 (36)258 (39)0.5749 (35)250 (39)0.41
        Nevirapine17 (15)116 (17)18 (13)115 (18)
        Efavirenz23 (20)134 (20)30 (22)127 (20)
        Delaviridine1 (1)10 (2)1 (<1)10 (2)
    Protease inhibitors68 (60)329 (49)0.0482 (59)315 (49)0.04
        Indinavir28 (25)91 (14)30 (22)89 (14)
        Nelfinavir21 (18)95 (14)18 (13)98 (15)
        Saquinavir hard gel7 (6)31 (5)10 (7)28 (4)
        Saquinavir soft gel2 (2)49 (7)8 (6)43 (6)
        Ritonavir <400 mg/day16 (14)99 (15)30 (22)85 (13)
        Ritonavir >400 mg/day9 (8)49 (7)16 (12)42 (7)
        Lopinavir/ritonavir9 (8)63 (9)16 (12)56 (9)
        Amprenavir4 (4)27 (4)6 (4)25 (4)
Alcoholic beverages*
    <798 (86)519 (7)0.16122 (88)495 (77)0.007
    7–1311 (10)96 (14)15 (11)92 (14)
    >145 (4)49 (7)2 (1)52 (8)
Physical activity
    Sedentary35 (31)204 (31)0.1247 (34)495 (77)0.19
    Low40 (35)167 (25)35 (25)172 (27)
    Moderate26 (23)192 (29)44 (32)174 (27)
    High13 (11)101 (15)13 (9)101 (16)
Dietary intent
    Increase weight22 (11)133 (20)0.00828 (20)117 (18)0.11
    Maintain weight81 (71)461 (69)88 (63)454 (71)
    Decrease weight21 (18)71 (11)23 (17)69 (11)
  • Data are means ± SD or n (%).

  • *

    * Standard drinks consumed each week. P values are for t test comparisons for antiretroviral drug use in those with and without metabolic syndrome. BP, blood pressure; CDC, Centers for Disease Control and Prevention; NRTI, nucleoside reverse transcriptase inhibitors; NNRTI, non-nucleoside reverse transcriptase inhibitors.